The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.01%	21.70%	★★★★★★
Krystal Biotech	29.09%	36.48%	★★★★★★
Reddit	21.88%	25.35%	★★★★★★
Fabrinet	21.38%	23.34%	★★★★★★
Sandisk	39.64%	36.56%	★★★★★★
Palantir Technologies	31.23%	32.17%	★★★★★★
Zscaler	14.44%	55.86%	★★★★★☆
Marker Therapeutics	64.28%	69.04%	★★★★★★
Tenaya Therapeutics	59.68%	60.87%	★★★★★☆
Intellia Therapeutics	55.83%	67.02%	★★★★★☆

We'll examine a selection from our screener results.

Rezolute (RZLT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Rezolute, Inc. is a late-stage rare disease company dedicated to enhancing outcomes for individuals with hypoglycemia due to hyperinsulinism in the United States, with a market cap of $417.87 million.

Operations: Rezolute, Inc. is engaged in the development of therapies targeting rare diseases, specifically focusing on hypoglycemia caused by hyperinsulinism. The company operates primarily within the United States and is in the late stages of its research and development efforts.

Rezolute's recent strides in addressing rare hyperinsulinism conditions through its innovative treatment, ersodetug, mark significant progress. The company reported a reduction in net losses to $16.17 million for Q3 2026 from $18.91 million the previous year, reflecting tighter financial management despite ongoing R&D expenses. Notably, the interim results from their Phase 3 upLIFT study showed promising efficacy with six out of eight participants achieving primary endpoints—this underscores Rezolute’s potential to meet urgent medical needs in niche markets. These developments could be pivotal as Rezolute aims for profitability and continues investing heavily in research to drive future growth and innovation within biotech sectors focused on rare diseases.

SELLAS Life Sciences Group (SLS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing novel cancer therapeutics in the United States, with a market cap of $1.46 billion.

Operations: SELLAS Life Sciences Group focuses on developing innovative cancer treatments in the U.S., operating as a late-stage clinical biopharmaceutical firm.

SELLAS Life Sciences Group, despite its challenges with profitability, shows promising growth prospects. With a forecasted annual revenue increase of 67.2%, the firm is set to outpace the US market average significantly. Recent presentations at various oncology forums underline SELLAS's commitment to advancing cancer treatment, particularly through its innovative CDK9 inhibitor, SLS009, which has demonstrated increased potency in preclinical trials against resistant acute myeloid leukemia strains. Furthermore, the company's strategic moves including a recent $150 million follow-on equity offering and continuous R&D investment underscore its aggressive pursuit of breakthroughs in targeted oncology therapies.

Larimar Therapeutics (LRMR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for rare diseases through its innovative cell penetrating peptide technology platform, with a market cap of $362.21 million.

Operations: Larimar Therapeutics is focused on advancing treatments for rare diseases through its proprietary cell penetrating peptide technology. As a clinical-stage biotechnology company, it does not currently generate revenue from product sales.

Larimar Therapeutics is navigating a transformative phase, underscored by its aggressive R&D strategy, which saw expenditures reaching $29.61 million in Q1 2026 alone, reflecting its commitment to pioneering treatments for Friedreich’s ataxia. Despite recent financial strains evidenced by a net loss of $62.5 million in the last fiscal quarter of 2025, Larimar's innovative approach includes the development of nomlabofusp—an investigational therapy that has shown promising results across multiple species and is poised for accelerated FDA approval pathways. This focus on specialized biologics could potentially establish Larimar as a leader in neurodegenerative disease therapeutics, aligning with broader industry trends towards targeted healthcare solutions.

Taking Advantage

• Unlock our comprehensive list of 68 US High Growth Tech and AI Stocks by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.